Low-dose CT chest scans could help detect pneumonia in at-risk patients while exposing them to only small amounts of radiation, a new study has found. The research, published in Radiology: Cardiothoracic Imaging, shows that ultra-low-dose scans can effectively detect pneumonia in patients with compromised immune systems, enabling doctors to treat the infection before it becomes life-threatening. According to the researchers, these scans expose patients to just 2% of the radiation dose used in a standard CT scan.

"This study paves the way for safer, AI-driven imaging that reduces radiation exposure while preserving diagnostic accuracy,” lead researcher Dr Maximiliano Klug, a radiologist with the Sheba Medical Center in Ramat Gan, Israel, said in a news release. He added that CT scans are the gold standard for detecting pneumonia but there are concerns regarding the risk posed by repeated exposure to radiation. There is a solution- ultra-low-dose CT scan. However, the problem is that these scans can be grainy and hard to read, researchers said.

Study Gives Solution To This

To overcome that, Klug's team developed an AI program that could help "de-noise" low-dose scans, making them sharper and easier to read. Between September 2020 and December 2022, 54 patients with compromised immune systems who had fevers underwent a pair of chest CT scans -- a normal dose scan and an ultra-low-dose scan. The AI program cleaned up the low-dose scan, and then both sets of images were given to a pair of radiologists for assessment. Radiologists had 100% accuracy in detecting pneumonia and other lung problems with the AI-cleaned low-dose scans, but 91% to 98% accuracy in examining the scans that hadn’t been improved through AI, results show.

"This pilot study identified infection with a fraction of the radiation dose," Klug said. "This approach could drive larger studies and ultimately reshape clinical guidelines, making denoised ultra-low dose CT the new standard for young immunocompromised patients.

How Can You Detect Pneumonia?

Pneumonia is a lung infection that causes the air sacs in the lungs to fill with fluid or pus and can be caused by bacteria, viruses, or fungi. The symptoms can range from milk to severe, which includes:

Coughing with or without cough

Fever

Chills

Trouble breathing

Chest pain, especially when breathing deeply or coughing

Sweating or chills

Rapid heart rate

Loss of appetite

Bluish skin, lips, and nails

Confusion.

How to detect Pneumonia in coughing newborns and toddlers?

Pneumonia can severely affect newborns and young children as their lungs are comparatively more sensitive. As per Dr Goyal, young children can cough for various reasons including seasonal infections and tonsillitis, which is very common in this age group. But if they look visibly irritable and have poor sleep patterns, then parents must reach out to an expert. "I am not saying that parents must visit a hospital but any local paediatrician would be able to detect pneumonia in your kid.

Children under 15 account for half of the 46 suspected mpox cases in Guinea-Bissau, which declared its first mpox outbreak on July 4, UNICEF said.

As of August 17, the country had reported seven confirmed cases, all among adults. Six were reported in the Autonomous Sector of Bissau and one in the Biombo Region. No deaths have been reported.

Of the 46 suspected cases, 23 are children under 15, including 16 aged 0-4 years. Young children face a greater risk of complications from mpox.

“This is the first time mpox cases have been reported in Guinea-Bissau, making even a small outbreak a major public health event,” said Sandra Martins, UNICEF Deputy Representative in Guinea-Bissau.

“While the country’s surveillance system remains extremely fragile, we face the risk that cases are going undetected, particularly among children who are the most vulnerable to severe complications.”

Concerns Over Undetected Transmission

UNICEF said the confirmed cases do not appear connected, raising concerns about undetected chains of transmission and additional unidentified cases.

Gaps remain in community-based surveillance, including contact identification, sample testing and tracing how the virus is spreading.

Martins urged families to seek care if a child or family member develops a rash, fever, swollen lymph nodes or other symptoms.

What Is Mpox?

Mpox is a viral zoonotic disease that can spread from animals to humans. It is caused by the monkeypox virus, part of the Orthopoxvirus genus, the same family as the variola virus that causes smallpox.

Symptoms of Mpox

Mpox symptoms are generally milder than those of smallpox. After an incubation period of 5 to 21 days, symptoms typically begin with fever, headache, muscle aches and fatigue.

The disease usually resolves within 2 to 4 weeks, but severe cases can occur, particularly in children, pregnant women and immunocompromised people. Common symptoms include:

• Skin rash
• Fever
• Sore throat
• Headache
• Body aches
• Back pain
• Low energy
• Swollen lymph nodes

How Does Mpox Spread?

Mpox can spread through direct contact with the blood, bodily fluids or skin lesions of infected animals, including rodents and primates.

Human-to-human transmission can occur through close contact with respiratory secretions, skin lesions or contaminated objects. The virus can enter through broken skin, the respiratory tract or the mucous membranes of the eyes, nose or mouth.

Mpox: How Can Children Be Protected?

The World Health Organization (WHO) and the Centers for Disease Control and Prevention (CDC) guidelines for preventing mpox transmission include:

• Avoid contact with animals that could harbor the virus, particularly in regions where mpox is endemic.
• Practice good hygiene by washing hands frequently with soap and water or using alcohol-based hand sanitizer.
• Use personal protective equipment (PPE) such as masks, gloves and gowns when caring for infected individuals.
• Isolate infected individuals from others who are at risk of contracting the virus.
• Get vaccinated where available. The smallpox vaccine has been shown to provide some protection against mpox, while newer vaccines specifically designed for mpox are being deployed.

The Centre has tightened restrictions on certain cough and cold medicines for children below four years, citing potential health risks associated with a specific drug combination in children.

The Union Health Ministry has restricted the manufacture, sale and distribution of fixed-dose combinations (FDCs) containing chlorpheniramine maleate and phenylephrine hydrochloride for children under four.

Manufacturers have also been instructed to carry a clear warning stating that the medicine “shall not be used in children below four years of age.”

The decision follows recommendations from an expert committee and the Drugs Technical Advisory Board (DTAB), which reviewed the safety of the combination in young children.

Why These Medicines Have Been Restricted?

Chlorpheniramine is an antihistamine, while phenylephrine is a decongestant. The combination is used to relieve symptoms like blocked or runny nose, sneezing and watery eyes caused by colds, flu and allergies.

However, young children can respond differently to medicines than adults, and dosing errors or adverse effects can result in more serious effects in this age group.

The Health Ministry’s expert committee concluded that the combination could pose potential health risks in children below four, particularly when safer alternatives are available.

The latest directive therefore requires manufacturers to clearly communicate the age restriction rather than putting the onus on parents.

Also read: FSSAI Orders Halt Of Ghee Sales Amid Adulteration Crackdown: How To Spot Fake Ghee & Its Effects On Your Health

Cough And Cold Medicines Are Not Always Needed In Young Children

A common cold is usually caused by a virus, meaning antibiotics do not treat it. In many children, symptoms improve with supportive care such as adequate fluids, rest and measures recommended by a paediatrician.

Combination cough and cold products can contain several active ingredients, increasing the possibility of incorrect dosing and side effects if parents give more than one medicine containing the same ingredient.

This is particularly important for young children because their medication doses are generally calculated according to age and/or body weight.

Also read: Shigellosis Cases In Kerala Raise AMR Concern: All About Complications Due To Drug-Resistant Shigella

Restriction Comes Amid Wider Scrutiny Of Cough Medicines

The government has been tightening oversight of paediatric medicines following serious concerns surrounding cough syrups in India.

In June, the Centre removed cough syrups from an exemption that had allowed certain products to be sold through retail outlets in smaller villages without the same pharmacy restrictions.

What Parents Should Do?

Parents should avoid giving children under four any medicine containing this combination unless specifically advised by a qualified healthcare professional.

• Before giving a cough or cold medicine to a child, parents should:
• Check the active ingredients, not just the brand name.
• Follow the dose prescribed by a paediatrician.
• Avoid combining multiple cold medicines without medical advice.
• Use the measuring device supplied with liquid medicines rather than household spoons.
• Never give a medicine prescribed for another child.
• Seek medical attention if a child’s symptoms are severe, persistent or worsening.

The government has emphasised that safer alternatives are available, while the latest restriction is intended to reduce avoidable medication-related risks in young children.

‘Scromiting’ is back in the news as emergency department visits in the US involving cannabis hyperemesis syndrome (CHS) were 3.7 times as high, according to a CDC report.

CHS is associated with frequent cannabis use and is characterized by episodes of severe nausea, vomiting and abdominal pain. The term “scromiting” refers to a combination of screaming and vomiting that can occur during severe episodes.

The CDC’s Morbidity and Mortality Weekly Report (MMWR), which analyzed data from January 2023 through May 2026, found that the rate of emergency department visits involving CHS remained largely steady from January 2023 through September 2025.

CHS is likely under-recognized in both adolescents and adults. Clinicians may not routinely assess or document cannabis use, while CHS can also be misdiagnosed as other gastrointestinal conditions, including cyclic vomiting syndrome.

To improve clinical identification, a specific International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) discharge diagnosis code for CHS was introduced on October 1, 2025. The CDC report examined CHS-related emergency department visits before and after the code was introduced.

The change was immediate. From September 2025 to October 2025, CHS-involved emergency department visits jumped from 3.35 per 10,000 to 11.26 per 10,000. The rate rose further to 13.10 per 10,000 by May 2026.

From October 2025 through May 2026, CHS-involved emergency department visits were 3.7 times as high as the monthly average recorded before the new diagnostic code was introduced.

The CDC noted that the new code made the condition easier to identify and track, meaning the sharp increase may partly reflect greater recognition and documentation of CHS.

Also read: Sugar Rationing In First 1,000 Days Linked To Lower Depression, Cancer Risk In Adulthood

What Is Cannabis Hyperemesis Syndrome?

CHS is a syndrome associated with prolonged, frequent cannabis use. It is characterized by sudden episodes of severe nausea, repeated vomiting and abdominal pain.

Reports of suspected CHS increased sharply between 2016 and 2022, with the largest increase occurring during the COVID-19 pandemic. The CDC noted that the rise also coincided with widespread state-level cannabis legalization in the US, although cannabis remains illegal under federal law.

People with CHS often seek medical care because symptoms can be severe and debilitating. Outcomes can range from resolution of symptoms after stopping cannabis use to, in rare cases, death.

When Was CHS First Identified?

CHS was first identified in Australia in 2004, yet nearly two decades later, the condition remains poorly understood. It typically affects people who use marijuana daily or near daily for more than a year. Symptoms can include severe nausea, repeated vomiting and abdominal pain, along with a compulsive desire to take extremely hot showers or baths.

Many patients report that heat temporarily eases their symptoms, although the relief is often short-lived.

Symptoms Can Last For Days

Read More: Scottish Toddler With Rare UV Disorder Gets UV-Safe Home: All About Inherited XP

CHS episodes can last for days, while recovery may take weeks or even months, depending on overall health, eating habits and whether the person stops using marijuana. Continuing to use cannabis can quickly trigger symptoms again.

A study from George Washington University found that nearly half of surveyed patients had been hospitalized at least once because of CHS. Many reported using marijuana more than five times a day before symptoms began. Starting cannabis at an early age was also linked to a higher likelihood of developing the condition.

Why Is CHS Still Poorly Understood?

Researchers emphasize that CHS is real, although many questions remain unanswered, including why hot showers provide temporary relief and how much cannabis use puts someone at risk.

Health experts say greater clinical awareness is needed. Better screening for cannabis use and recognition of symptom patterns could help reduce misdiagnosis and guide patients towards the only proven treatment: stopping marijuana use.